"New kid on the block"-MDDM as a new ingredient in Ecstasy tablets

Ecstasy tablets are commonly associated with 3,4-methylenedioxy-methamphetamine (MDMA), but they often contain diverse psychoactive substances, including new psychoactive substances (NPS), which pose significant risks to users due to unknown composition and effects. This study analyzed 150 Ecstasy tablets seized in Poland between 2020 and 2021, shaped as "Stormtrooper" heads, to identify their chemical composition. Using gas chromatography-mass spectrometry (GC-MS) and ultra-high-performance liquid chromatography with photodiode array detection (UHPLC-PDA), we detected MDMA, 3,4-methylenedioxyamphetamine (MDA), and for the first time in Polish seizures, a novel phenylethylamine derivative-3,4-methylenedioxy-N,N-dimethylamphetamine (MDDM). MDDM, a methyl analogue of MDMA and dimethyl analogue of MDA, has limited pharmacological data and reportedly mild psychoactive effects. Its presence is likely linked to impurities or by-products formed during illicit MDMA synthesis. Quantitative analysis revealed that MDA occurred in the highest concentrations per tablet (26-74 mg), followed by MDDM (11-28 mg) and MDMA (3-11 mg). Although MDDM alone is considered to have low potency, its co-occurrence with other phenylethylamines may produce synergistic effects, potentially increasing toxicity. These findings shed light on synthetic routes in illicit MDMA production and highlight the unpredictable chemical composition of street drugs. The detection of multiple active substances-even at low doses-raises significant public health concerns, highlighting the necessity for continuous forensic monitoring and increased awareness of the dynamic and complex nature of synthetic drug markets.